Washington University

Other

Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.

Daved Henry Fremont

Christopher Nelson

Eric Reed Lazear

Alexander Sasha Krupnick

Michael S Diamond

Steven Teitelbaum

Julia T Warren

Sebastian Ulbert

Andrew E Gelman

Larissa Thackray

Ted H Hansen

Michael Miley

John Westwick

Katherine Basore

Arthur Kim

Estefania Fernandez

Haiyan Zhao

Derek Platt

Rong Zhang

Grant Nybakken

Steven Truscott

Vesselin Mitaksov

Lonnie Lybarger

Janet Connolly

Stefan Chabierski

Yun Hsuan Lu

Olga Lubman

Among the various aspects of the present disclosure is the provision of compositions and methods of treating arthritogenic alphavirus infection and methods of screening.

Compositions and methods for inhibition of alphavirus infection

The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to an NKG2D ligand or PD1 ligand and may improve immunotherapy by limiting side effects associated with immunotherapy. The present disclosure also encompasses compositions and methods for recruiting cytotoxic lymphocytes to target cells using NKG2D receptor ligands or PD1 ligands. The compositions disclosed herein comprise a NKG2D receptor ligand and a targeting molecule and may improve immunotherapy by limiting side effects associated with immunotherapy.

Compositions and methods for targeted cytokine delivery

The present disclosure relates to antibodies specific to Zika virus and methods for detecting Zika virus infection in a subject. The present disclosure also relates to therapeutic antibodies useful in reducing viral load.

Antibodies to zika virus and methods of use thereof

The present disclosure encompasses compositions and methods for targeted cytokine delivery. The compositions disclosed herein comprise a cytokine linked to a ligand and may improve immunotherapy by limiting side effects associated with immunotherapy.

The present disclosure generally provides compositions and methods related to the field of immunology. Specifically, disclosed herein are chemokine binding proteins and methods of use thereof.

Chemokine decoy receptors of rodent gammaherpesviruses and uses thereof

Methods for constructing efficient inhibitors of target TNF superfamily receptors, single chain target TNF superfamily ligands that inhibit of target TNF superfamily receptors while failing to engage or inhibit non-target TNF superfamily receptors, and methods of their use to treat diseases are provided. Single chain RANKL, TNF, and TRAIL ligands that effectively inhibit their target receptors while failing to inhibit non-target TNF superfamily receptors are also provided.

Mutant tumor necrosis factor receptor superfamily (TNFsfR) ligands and methods of making and using same

Oligomers for TNF superfamily inhibition, methods of making and using

The present invention relates to mutant peptides of the E protein of the West Nile virus and other flaviviruses useful for discriminating flaviviral infections, as well as kits, methods and uses related thereto.

Distinguishing flavivirus infection using a recombinant mutant envelope protein

Oligomers for TNF superfamily inhibition

A disulfide trap, comprising an antigen peptide covalently attached to an MHC class I heavy chain molecule by a disulfide bond extending between two cysteines, is disclosed. In some configurations, a disulfide trap, such as a disulfide trap single chain trimer (dtSCT), can comprise a single contiguous polypeptide chain. Upon synthesis in a cell, a disulfide trap oxidizes properly in the ER, and can be recognized by T cells. In some configurations, a peptide moiety of a disulfide trap is not displaced by high-affinity competitor peptides, even if the peptide binds the heavy chain relatively weakly. In various configurations, a disulfide trap can be used for vaccination, to elicit CD8 T cells, and in multivalent MHC/peptide reagents for the enumeration and tracking of T cells. Also disclosed are nucleic acids comprising a sequence encoding a disulfide trap. Such nucleic acids, which can be DNA vectors, can be used as vaccines.

Disulfide trap MHC class I molecules and uses therefor

The present invention provides crystalline forms of domain III of the West Nile Virus ('WNV') envelope protein in complex with a Fab fragment of a neutralizing antibody, methods of obtaining such crystals and high-resolution structures and atomic structure coordinates. The crystals of the invention and the atomic structural information are useful for solving crystal and solution structures of related and unrelated proteins, and for screening for, identifying or designing compounds or antibodies that bind to, modulate a biological activity of, or neutralize infection mediated by flaviviral envelope proteins.

Crystals and structure of domain III of West Nile Virus envelope protein in association with a Fab fragment of a neutralizing antibody

Growing community of inventors

St. Louis, MO, United States of America

Daved Henry Fremont